![]() |
Trials |
A phase I multicenter open-label study of BGB324 as a single agent and in combination with cytarabine in patients with acute myeloid leukemia or high/intermediate (int-2) risk myelodysplastic syndrome wich overexpresses axlCancer type: Leukemia Phase: I Principal Investigator: Gjertsen Bjørn Tore Country: NO Keywords: Norway, Bergen Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02488408?term=BGBC003&rank=1 |